News

Max Scherzer received a cortisone injection as treatment for the sore right thumb that ended his Toronto Blue Jays debut ...
Max Scherzer knew this was a possibility, and now he’s sidelined for the foreseeable future. Already dealing with a thumb injury that he said could “blow up fast” and “lead to a lot of ...
Speaking with reporters after the game, Scherzer announced the unfortunate news that he will not make his next start. He ...
The Toronto Blue Jays put right-hander Max Scherzer on the 15-day injured list Sunday because of inflammation in his right ...
Max Scherzer continues to deal with injury woes to start off his Toronto Blue Jays career. Scherzer got the start for the Blue Jays during Saturday’s game against the Baltimore Orioles at Rogers ...
The big move of the fire sale was when the Mets shipped Max Scherzer to the Texas Rangers in exchange for Luisangel Acuña, with Scherzer then telling the media that he was told the Mets were ...
Scherzer pitched three innings versus the Orioles on Saturday before leaving with soreness in his right lat muscle.
TORONTO -- The Blue Jays put right-hander Max Scherzer on the 15-day injured list Sunday because of inflammation in his right thumb. The move comes one day after the three-time Cy Young Award ...
Toronto Blue Jays' pitcher Max Scherzer has been placed on a 15-day injured list due to inflammation in his right thumb. The injury, which has persisted since spring training, was aggravated after ...
While the Toronto Blue Jays drew a lot of criticism for their mostly underwhelming offseason, signing Max Scherzer to a one-year deal was not a move Ross Atkins deserved to be ridiculed for.
Max Scherzer is now with a new team, but he is still apparently dealing with an old injury issue. The Toronto Blue Jays righty Scherzer spoke to reporters on Monday and made a concerning ...
Max Scherzer received a cortisone shot to treat the inflammation in his right thumb, the future Hall of Famer told reporters (including Ben Nicholson-Smith of Sportsnet). The Jays will have a ...